{"aliases":[{"type":"CodeName","name":"BMS-562247-01"},{"type":"ChemicalStructureName","name":"aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,4R,6S,8S)-4-(1,1-difluoroethyl)-1,3,4,5,6,7,8,9-octahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2β,3β,4β,5α,12R,19.alpha.)-, (2R,3R)-2,3-dihydroxybutanedioate (1:2)"},{"type":"CodeName","name":"BMS-562247"},{"type":"USBrandName","name":"Eliquis"},{"type":"ChemicalStructureName","name":"1H-Pyrazolo(3,4-c)pyridine-3-carboxamide, 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxo-1-piperidinyl)phenyl)-"},{"type":"CASRegistryName","name":"503612-47-3"}],"definition":{"html":"An orally active inhibitor of coagulation factor Xa with anticoagulant activity. Apixaban directly inhibits factor Xa, thereby interfering with the conversion of prothrombin to thrombin and preventing formation of cross-linked fibrin clots. \n","text":"An orally active inhibitor of coagulation factor Xa with anticoagulant activity. Apixaban directly inhibits factor Xa, thereby interfering with the conversion of prothrombin to thrombin and preventing formation of cross-linked fibrin clots. \n"},"drugInfoSummaryLink":null,"nciConceptId":"C61308","nciConceptName":"Apixaban","termId":484444,"name":"apixaban","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"apixaban"}